Indexado en

Licencia y uso

Citaciones

Cited 1 times in

Cited 2 times in

Altmetrics

Grant support

This work was supported by Peaches Biotech/R4T and by Government of Aragon grant B31_20R.

Análisis de autorías institucional

Compartir

Evaluation in a Cytokine Storm Model In Vivo of the Safety and Efficacy of Intravenous Administration of PRS CK STORM (Standardized Conditioned Medium Obtained by Coculture of Monocytes and Mesenchymal Stromal Cells)

Publicado en:Biomedicines. 10 (5): 1094- - 2022-05-01 10(5), DOI: 10.3390/biomedicines10051094

Autores: Lapuente, JP; Gomez, G; Marco-Brualla, J; Fernandez, P; Desportes, P; Sanz, J; Garcia-Gil, M; Bermejo, F; San Martin, JV; Algaba, A; De Gregorio, JC; Lapuente, D; De Gregorio, A; Lapuente, B; Gomez, S; Andres, MD; Anel, A

Afiliaciones

Resumen

Our research group has been developing a series of biological drugs produced by coculture techniques with M2-polarized macrophages with different primary tissue cells and/or mesenchymal stromal cells (MSC), generally from fat, to produce anti-inflammatory and anti-fibrotic effects, avoiding the overexpression of pro-inflammatory cytokines by the innate immune system at a given time. One of these products is the drug PRS CK STORM, a medium conditioned by allogenic M2-polarized macrophages, from coculture, with those macrophages M2 with MSC from fat, whose composition, in vitro safety, and efficacy we studied. In the present work, we publish the results obtained in terms of safety (pharmacodynamics and pharmacokinetics) and efficacy of the intravenous application of this biological drug in a murine model of cytokine storm associated with severe infectious processes, including those associated with COVID-19. The results demonstrate the safety and high efficacy of PRS CK STORM as an intravenous drug to prevent and treat the cytokine storm associated with infectious processes, including COVID-19.

Palabras clave